MedTrace Logo

Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

NCT00435955 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2007-02-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether an intensified treatment plus Rituximab followed by autologous transplantation is superior to a conventional chemotherapy regimen also supplemented with Rituximab.

Conditions

Interventions

PROCEDURE

High dose chemotherapy with autologous transplantation

DRUG

Rituximab

Sponsors & Collaborators

  • University of Turin, Italy

    collaborator OTHER

  • Gruppo Italiano Trapianto di Midollo Osseo

    collaborator OTHER

  • Gruppo Italiano Studio Linfomi

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Corrado Tarella, MD · Università di Torino, Azienda Ospedaliera San Giovanni Battista

  • Marco Ladetto, MD · Università di Torino Azienda Ospedaliera San Giovanni Battista

  • Alessandro Pileri, MD · Università di Torino Azienda Ospedaliera San Giovanni Battista (Now retired)

  • Mario Boccadoro · Università di Torino/Azienda Ospedaliera San Giovanni Battista B

  • Alessandro Gianni · Istituto Tumori di Milano, Milano Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435955 on ClinicalTrials.gov